COMPASS PATHWAYS PLC -
5.3000
07-November-24 14:59:59
15 minutes delayed
Stocks
+0.5700
+12.05%
Today's range
4.7500 - 5.4700
ISIN
N/A
Source
NASDAQ
-
COMPASS Pathways to participate in upcoming Jefferies Healthcare Conference
26 May 2023 15:00:00 By Nasdaq GlobeNewswire
-
26 May 2023 06:00:00 By Nasdaq GlobeNewswire
-
COMPASS Pathways Announces First Quarter 2023 Financial Results and Business Highlights
11 May 2023 06:00:00 By Nasdaq GlobeNewswire
-
COMPASS Pathways plc to announce first quarter 2023 financial results on 11 May 2023
03 May 2023 15:01:00 By Nasdaq GlobeNewswire
-
American Medical Association to Issue First New Code for Psychedelic Therapies
02 May 2023 06:00:00 By Nasdaq GlobeNewswire
-
COMPASS Pathways to participate in upcoming 22nd Annual Needham Virtual Healthcare Conference
10 Apr 2023 09:10:13 By Nasdaq GlobeNewswire
-
02 Mar 2023 09:23:22 By Nasdaq GlobeNewswire
-
24 Feb 2023 11:01:00 By Nasdaq GlobeNewswire
-
08 Dec 2022 03:00:00 By Nasdaq GlobeNewswire
-
COMPASS Pathways to participate in upcoming Evercore ISI HealthCONx Conference
28 Nov 2022 15:01:00 By Nasdaq GlobeNewswire
-
COMPASS Pathways Announces Third Quarter 2022 Financial Results and Business Highlights
03 Nov 2022 06:00:00 By Nasdaq GlobeNewswire
-
03 Nov 2022 05:00:00 By Nasdaq GlobeNewswire
-
COMPASS Pathways plc to announce third quarter 2022 financial results on 3 November 2022
26 Oct 2022 15:00:00 By Nasdaq GlobeNewswire
-
12 Oct 2022 10:00:00 By Nasdaq GlobeNewswire
-
COMPASS Pathways to Hold Virtual Capital Market Day on 12 October 2022
04 Oct 2022 08:05:40 By Nasdaq GlobeNewswire
-
COMPASS Pathways to participate in upcoming Jefferies Innovation in Mental Health Summit
19 Sep 2022 15:01:00 By Nasdaq GlobeNewswire
-
COMPASS Pathways to participate in three upcoming investor events
01 Sep 2022 07:06:21 By Nasdaq GlobeNewswire
-
COMPASS Pathways plc announces second quarter 2022 financial results and business highlights
04 Aug 2022 06:00:00 By Nasdaq GlobeNewswire
-
02 Aug 2022 15:05:00 By Nasdaq GlobeNewswire
-
COMPASS Pathways launches phase II clinical trial of psilocybin therapy in anorexia nervosa
28 Jul 2022 03:00:00 By Nasdaq GlobeNewswire